OR WAIT 15 SECS
Bayer (Berlin, Germany) has announced that its Canadian organization Bayer Inc. (Mississauga, ON) will partner with the Population Health Research Institute (PHRI, Hamilton, ON) in launching a major clinical research program aimed at identifying potential treatments against COVID-19. The two studies will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b. Bayer will make a financial commitment of CAD 1.5 million (approx. €1 million) towards the studies and will supply study drugs to support the research. This adds to the CAD 0.5 million committed by the PHRI earlier this month which enabled the development of the research program. PHRI plans to enroll 6,000 patients into the two studies from more than 60 contributing research sites across the Canadian province of Ontario and internationally.